Please login to the form below
IBD
This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.
M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards
Sponsored by Cloud Talk. Winner: LOGIC IBD Nurse Education and Recognition Event.
Latest news
-
Latecomer Lilly preps its IL-23 drug for Crohn’s disease
Tremfya also has data suggesting it works in Stelara-resistant psoriasis. Lilly’s antibody is still in phase 3 for psoriasis, well behind the leaders, but IBD presents a greater opportunity
-
Finch’s microbiota drug for C. diff gets FDA breakthrough status
Finch's CEO Mark Smith. Led by CEO Mark Smith, the company also has a two-year-old deal with Takeda to develop a microbiota treatment for irritable bowel disease (IBD).
-
BMS to test Vedanta’s bacterial therapy with Opdivo
The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in
-
Communiqué: big wins for obesity and sugar tax campaigners
Specialist healthcare communications group Sciterion (pictured below) won the Excellence in Communications via a Live Event or Stand-Alone Activity accolade for its Live Multi-site National IBD Meeting. ... Meanwhile, Aurora Healthcare Communications’
-
Communiqué 2018 - all the winners
Excellence in Communications via a Live Event or Stand-Alone Activity. Live Multi-site National IBD Meeting by Sciterion for AbbVie. ... Travel with IBD by Aurora Healthcare Communications for Takeda and Crohns Colitis UK.
More from news
Approximately 11 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)
-
Deal Watch June 2016
IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.
-
Deal Watch October 2015
Janssen's partnership with Canadian biotech enGene, facilitated through J&J Innovation, brings gene therapies for inflammatory bowel disease (IBD) and includes an undisclosed upfront payment and equity investment, R&D ... Research collaboration, option,
-
Pharma deals in June 2015
the treatment of inflammatory bowel disease (IBD). ... 130. Lycera Corporation/ Celgene Corporation. Orally bioavailable RORgamma agonists for ex vivo use lead programme, LYC-30937 (oral gut-directed ATPase modulator for IBD, p1).
-
Getting real about patient support
opposed to a series of acute episodes (such as in asthma, COPD or IBD).
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Takeda strengthens leadership team with business unit director
Takeda UK has appointed Craig Adkins as its new business unit director for irritable bowel disease (IBD). .
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Lucid Group strengthens its scientific leadership and client service team with two new hires
Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno-oncology, CIA, CKD, oral contraception, IBD, and wound care.
-
IBD Registry appoints first CEO
The IBD Registry is familiar to many as the first UK-wide collection of anonymised adult and paediatric IBD data for prospective audit and research. ... Liz brings to the IBD Registry 20 years of executive and senior management experience from the
-
Pharma and NHS working together for patients - the IBD Registry Industry Working Group
Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile.
-
Joined-up thinking on anaemia
Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated. ... The partners share resources and skills and the project is the first to use the IBD
-
Innovation in pharma: the highs and lows of the current healthcare economy
the use of biosimilars used to fund additional specialist IBD (inflammatory bowel disease) nurses to improve standards of care in areas where service support is thin on the ground.
More from PMHub
Approximately 3 fully matching, plus 17 partially matching documents found.
Featured jobs
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
Subscribe to our email news alerts
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- AstraZeneca buys FDA priority review voucher from Sobi
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
JPA Health Communications
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
